Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2570358 | 0.95 | NCOA1 (0.41) | NCOA1NCOA3TDP1MEN1GAA | |
| SCHEMBL2563640 | 0.94 | MEN1 (0.42) | NCOA1NCOA3TDP1MEN1KMT2A | |
| SCHEMBL2566109 | 0.92 | RAB9A (0.39) | NCOA1NCOA3MEN1GAAKMT2A | |
| SCHEMBL2563751 | 0.88 | EPHX2 (0.42) | NCOA1NCOA3FABP3FABP4TDP1 | |
| SCHEMBL2563906 | 0.86 | CA1 (0.41) | KMT2A | |
| SCHEMBL2564561 | 0.85 | MEN1 (0.45) | MEN1GAAKMT2ACYP3A4 | |
| SCHEMBL2565776 | 0.84 | CA1 (0.41) | RAB9ANPC1 | |
| SCHEMBL2563594 | 0.83 | HRH3 (0.41) | GAAKMT2A | |
| SCHEMBL2566106 | 0.82 | MEN1 (0.52) | MEN1GAAKMT2A | |
| SCHEMBL2570894 | 0.81 | NCOA1 (0.42) | NCOA1NCOA3TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | claimed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | claimed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | claimed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| EP-2383267-A1 | Substituted sulfonamide derivatives | Grünenthal GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | NCOA1 1250/4885NCOA3 1411/4885FABP3 2940/4885 |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | NCOA1 1250/4885NCOA3 1411/4885FABP3 2940/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | NCOA1 1250/4885NCOA3 1411/4885FABP3 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.